|
|
 | | | |
- close
- close
- close
- close
Novo Nordisk A/S (NVO) |
FierceBiotech
May 21
Comment
Turns out there was some truth behind the rumors that 3i was shopping the anti-infectives company Xellia.
FiercePharma
May 21
Comment
Novo A/S, the Danish holding company of and major shareholder in Novo Nordisk, said today it is pursuing a new piece of its investment strategy focused on more well-established companies as it announced the $700 million purchase of anti-infectives...
FierceBiotech
May 17
Comment
In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients.
StreetInsider.com
May 17
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Novo+Nordisk+%28NVO%29+Reports+Positive+Results+from+Paradigm+2/8350110.html for the full story.
Stock Blog Hub
May 16
Comment
Novo Nordisk A/S (NVO) and Emisphere Technologies, Inc. (EMIS) recently announced that they have modified their agreement for the development and commercialization of oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonist...
Resource Investor
May 16
Comment
Novo is chasing a lead in Australia currently that could be the next Witwatersrand, South Africa’s mother lode and the world’s richest gold field. Quinton Hennigh discusses what makes this find so special in this podcast.
FiercePharma
May 16
Comment
If austerity-minded governments aren't willing to pay for new drugs, then his company may have to choose not to launch new products there, choosing on a country-by-country basis where to do so.
FiercePharma
May 8
Comment
Novo Nordisk and its profit-growth plans hit a roadblock earlier this year when the FDA refused to approve its new diabetes drug, Tresiba, without a new safety study. But CEO Lars Sorensen thinks he has an alternate route through a new weight-loss...
FiercePharma
May 1
Comment
When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk, the world's largest insulin maker, focused on a rapidly growing...
Wall Street Journal
May 1
Comment
Novo Nordisk said its Tresiba drug may not hit the lucrative American market until as late as 2018, the latest wrinkle in the costly setback to its ambitions of launching this year and potentially getting a head start on competitors.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
